09:47 AM EST - Neovasc Inc. : reported that final data from its COSIRA trial assessing the efficacy and safety of the Neovasc ReducerTM, a novel percutaneous device for the treatment of refractory angina, was presented on March 29, in a Featured Clinical Research Presentation at ACC.14, the American College of Cardiology 63rd Annual Scientific Session & Expo. Neovasc Inc.
shares V.NVC are trading up $0.10 at $6.80.
